"The Report Humira
(adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to
2023 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Description
Humira (adalimumab)
(Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints. It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Humira (adalimumab) is a
recombinant, fully-human, IgG1 mAb that binds to TNFa and blocks its
interaction with the p55 and p75 cell-surface receptors, which
reduces inflammation and prevents tissue destruction. It was the
first fully-humanized mAb TNF inhibitor to enter the market for the
treatment of RA.
View
Full Report at http://www.marketresearchreports.biz/analysis/247122
Scope
- Overview of Rheumatoid
Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on
Humira (Adalimumab) including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for Humira
(Adalimumab) for the top 9 countries from 2013 to 2023.
- Sales information covered
for the US, France, Germany, Italy, Spain, the UK, Japan, Australia
and China.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Humira
(Adalimumab) performance.
- Obtain sales forecast for
Humira (Adalimumab) from 2013-2023 in top 9 countries (the US,
France, Germany, Italy, Spain, the UK and Japan, Australia and
China).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs for the Treatment of RA 32
4.1.4 Clinical Practice 33
5 Competitive Assessment 39
5.1 Overview 39
6 Humira (adalimumab) 41
6.1 Overview 41
6.2 Efficacy 43
6.3 Safety 43
6.4 SWOT Analysis 44
6.5 Forecast 44
7 Appendix 46
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment